Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RevMikeB who wrote (23153)	7/14/1998 12:33:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

The street has pretty much ignored the SRGN deal and teh ONTAK approval rec. The price did dip a bit when the FDA letter was announced, but misleading info was posted by some of our naysayers, and some investors probably bought that story (at least for a short time). Now however, LGND is focusing more and more on products and profits, so the street may give the final approval a positive response, especially since the deal should generate profits as early as next year (or possible by 4Q of this year)..

To: RevMikeB who wrote (23153)	7/14/1998 9:17:00 AM
From: jayhawk969	Respond to of 32384

<I was wondering if most of the people on the this thread believe that if Ontack is approved by FDA, Ligand's stock will go up on the news? With the 36 million payment that would be due, it makes me wonder. SRGN will go up, but what about LGND, and how much would you guess it will move?> If for some reason Ontak were not to be approved you can count on the stock going down. At that point Ligand is obligated to buy a dead horse. With Ontak approval an additional payment is necessary in cash or stock that will be offset by sales and revenue. I personally expect a bump of .50 to $1.00 per share as a result of the approval. SRGN should increase by 10 to 12 cents per share over current levels.